Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Malaria
Interventions
P. vivax challenge agent derived from PvHMB-CCE001
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Abbott ESA Chagas Assay Post-Market Study

NCT01662362
Conditions
Chagas Disease
Interventions
Testing Donor Specimens with ESA Chagas
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
17 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Rosemont, Illinois • Gaithersburg, Maryland
Conditions
Malaria
Interventions
Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 1 Interventional Accepts healthy volunteers

Adenovirus Vaccine for Malaria

NCT00371189
Conditions
Plasmodium Falciparum Infection
Interventions
Placebo, Ad35.CS.01 Circumsporozoite Malaria Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
2
States / cities
Stanford, California • Nashville, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial to Evaluate CIS43LS in Healthy Adults

NCT04206332
Conditions
Malaria
Interventions
VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Conditions
Trichotillomania
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Malaria, Malaria,Falciparum
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Acanthamoeba Keratitis
Interventions
Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo
Drug · Other
Lead sponsor
Jeremy Keenan, MD, MPH
Other
Eligibility
8 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 10 more
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Nitazoxanide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine Thorough QTc Study in Healthy Subjects

NCT01928914
Conditions
Malaria, Vivax
Interventions
Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Culver City, California • Baltimore, Maryland
Conditions
Malaria
Interventions
Artemether-lumefantrine
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 1 Interventional Accepts healthy volunteers

rCSP/AP10-602 [GLA-LSQ] Vaccine Trial

NCT03589794
Conditions
Plasmodium Falciparum Infection
Interventions
AP10-602, Malaria challenge, rCSP
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Malaria
Interventions
Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Malaria
Interventions
AMA1-C1/Alhydrogel + CPG 7909 (Saline), AMA1-C1/Alhydrogel + CPG 7909 (Phosphate), AMA1-C1/Alhydrogel + CPG 7909
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Conditions
Bacterial Vaginosis, Vaginal Microbiome, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginitis
Interventions
Menstrual Cup
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Chagas Disease
Interventions
Benznidazole, Placebo Oral Tablet
Drug
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
13 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
San Diego, California • New Orleans, Louisiana
Completed Phase 2 Interventional Results available

Sodium Stibogluconate Treatment of Leishmaniasis

NCT00662012
Conditions
Leishmaniasis
Interventions
Sodium Stibogluconate (SSG)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Oral E1018 in Healthy Adult Participants

NCT06854042
Conditions
Malaria, Healthy Participants
Interventions
E1018, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Conditions
Trichomonas Infections
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
Flowood, Mississippi • Jackson, Mississippi
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine

NCT01024686
Conditions
Malaria
Interventions
p52-/p36- GAP Vaccine
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Silver Spring, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine/Chloroquine DDI Study

NCT00871156
Conditions
Malaria
Interventions
Chloroquine, Tafenoquine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York